Yves Cornellier, President and Chief Executive Officer
Yves is a veteran marketing and sales professional with more than 30 years in the healthcare industry and extensive experience negotiating licensing and collaboration agreements with large pharmaceutical companies, biotechnology companies and institutions. Prior to joining Alethia, Yves was Senior Vice President, Business Development for LAB International Inc. since October 2003, subsequent to the acquisition of Seyvika Pharmaceuticals for which he was the founder. Prior, he held the position of Vice-President, Business Development and Commercialization at Theratechnologies, and also held the position of Director of Business Development and Senior Marketing Manager, Pharmaceuticals Product Division, for Abbott Laboratories Ltd. He also had the opportunity to work for Glaxo Canada and Miles Laboratories Canada in management positions of increasing responsibility including sales management, marketing, business unit management and strategic development. Yves has been and still is a member of the Board of Directors of several organizations.
Mario Filion, Ph.D., Executive Vice-President and Chief Scientific Officer
Mario was involved in the creation of Alethia in 2002. In his current position, he oversees Alethia’s operations including research and development, pre-clinical studies, collaborations with Universities . Prior, he acted as President of the Clinical Genomics Unit at SignalGene. Prior to joining SignalGene, Mario served as Director, Biotechnology at T2C2/Bio, a leading venture capital fund in Montréal. Earlier in his career, he acted as Director, Molecular Genetics of Algène Biotechnologies. Mario holds a Ph.D. degree in molecular biology from l’Université de Montréal and was an NSERC and FRSQ post-doctoral fellow at McGill University.
Jacques Jolivet, M.D., Chief Medical Officer
Dr. Jolivet brings to Alethia over 25 years of expertise as both a corporate executive as well as a practicing clinical oncologist. Prior to joining Alethia, Dr. Jolivet served as Senior Vice-President, Clinical Development at Aegera Therapeutics. Previously, he served as Director of Clinical Development, Oncology at Shire Pharmaceuticals and its predecessor, BioChem Pharma, where he played a key role in the development of Troxatyl. Dr. Jolivet maintains a clinical oncology practice at the Hematology and Medical Oncology department of the Hôtel Dieu Hospital of St.-Jerôme. Dr. Jolivet received his medical degree from l’Universite de Montreal, and completed his residency in internal medicine at the Royal Victoria Hospital. He completed a 3-year fellowship in anticancer drug pharmacology at the National Cancer Institute in Besthesda, MD. Dr. Jolivet led a research laboratory at the University of Montreal for 15 years, and has received numerous grants and awards for his research culminating in two issued US patents and more than 80 published papers.
Julie Laurin, B. Pharm., Ph.D., Director, Preclinical Drug Development
Julie is overseeing the preclinical development program of Alethia Biotherapeutics’ lead candidates. She has more than 15 years of experience in the pharmaceutical industry with extensive experience in preclinical and clinical development projects. Prior to joining Alethia Biotherapeutics, she held various progressive positions at BELLUS Health/Neurochem Inc. during a 14-year period to Director of Preclinical Research and Clinical Research. Julie is a pharmacist and holds a Ph.D. in Pharmaceutical Sciences from the Université de Montréal with a focus in pharmacokinetic and pharmacodynamic modeling.